Skip to main content
. 2017 Jul 22;8(37):62261–62273. doi: 10.18632/oncotarget.19446

Table 1. Characteristics of patients with esophageal carcinomas in SEER database.

Characteristics Total Married Unmarried Divorced Single Widowed
15598 (100%) 9279 (59.49%) 6319 (40.51%) 1971 (12.64%) 2592 (16.62%) 1756 (11.26%)
Sex
 Male 12581 (80.66%) 8093 (87.22%) 4488 (71.02%) 1555 (78.89%) 2083 (80.36%) 850 (48.41%)
 Female 3017 (19.34%) 1186 (12.78%) 1831 (28.98%) 416 (21.11%) 509 (19.64%) 906 (51.59%)
Race
 White 13241 (84.89%) 8297 (89.42%) 4944 (78.24%) 1629 (82.65%) 1879 (72.49%) 1436 (81.78%)
 Black 1583 (10.15%) 480 (5.17%) 1103 (17.46%) 273 (13.85%) 609 (23.50%) 221 (12.59%)
 Other race 774 (4.96%) 502 (5.41%) 272 (4.30%) 69 (3.50%) 104 (4.01%) 99 (5.64%)
Age
 <40 216 (1.38%) 103 (1.11%) 113 (1.79%) 16 (0.81%) 95 (3.67%) 2 (0.11%)
 41-55 2985 (19.14%) 1604 (17.29%) 1381 (21.85%) 466 (23.64%) 863 (33.29%) 52 (2.96%)
 56-70 7233 (46.37%) 4565 (49.20%) 2668 (42.22%) 1062 (53.88%) 1175 (45.33%) 431 (24.54%)
 71-85 4416 (28.31%) 2687 (28.96%) 1729 (27.36%) 399 (20.24%) 396 (15.28%) 934 (53.19%)
 >85 748 (4.80%) 320 (3.45%) 428 (6.77%) 28 (1.42%) 63 (2.43%) 337 (19.19%)
Histology
 ESCC 4725 (30.29%) 2231 (24.04%) 2494 (39.47%) 696 (35.31%) 1071 (41.32%) 727 (41.40%)
 EAC 9530 (61.10%) 6193 (66.74%) 3337 (52.81%) 1119 (56.77%) 1348 (52.00%) 870 (49.54%)
 Others 1343 (8.61%) 855 (9.21%) 488 (7.72%) 156 (7.91%) 173 (6.67%) 159 (9.05%)
Grade
 Well differentiated 844 (5.41%) 507 (5.46%) 337 (5.33%) 100 (5.07%) 136 (5.25%) 101 (5.75%)
 Moderately differentiated 6276 (40.24%) 3592 (38.71%) 2684 (42.48%) 834 (42.31%) 1120 (43.21%) 730 (41.57%)
 Poorly differentiated 8172 (52.39%) 5002 (53.91%) 3170 (50.17%) 1009 (51.19%) 1290 (49.77%) 871 (49.60%)
 Undifferentiated 306 (1.96%) 178 (1.92%) 128 (2.03%) 28 (1.42%) 46 (1.77%) 54 (30.75%)
Location
 Upper third of esophagus 1053 (6.75%) 481 (5.18%) 572 (9.05%) 167 (8.47%) 245 (9.45%) 160 (9.11%)
 Middle third of esophagus 3186 (20.43%) 1595 (17.19%) 1591 (25.18%) 459 (23.29%) 655 (25.27%) 477 (27.16%)
 Lower third of esophagus 11359 (72.82%) 7203 (77.63%) 4156 (65.77%) 1345 (68.24%) 1692 (65.28%) 1119 (63.72%)
TNM Stage
 Stage I 2548 (16.34%) 1495 (16.11%) 1053 (16.67%) 266 (13.50%) 385 (14.85%) 402 (22.89%)
 Stage II 3317 (21.27%) 1949 (21.00%) 1368 (21.65%) 428 (21.71%) 524 (20.22%) 416 (23.69%)
 Stage III 3733 (23.93%) 2299 (24.78%) 1434 (22.69%) 487 (24.71%) 595 (22.96%) 352 (20.04%)
 Stage IV 6000 (38.47%) 3536 (38.11%) 2464 (38.99%) 790 (40.08%) 1088 (41.98%) 586 (33.37%)
Therapy
 No surgery or radiotherapy 10247 (65.69%) 5608 (60.44%) 4639 (73.41%) 1371 (69.56%) 1854 (71.53%) 1414 (80.52%)
 Only surgery 2107 (13.51%) 1393 (15.01%) 714 (11.30%) 224 (11.36%) 319 (12.31%) 171 (9.74%)
 Only radiotherapy 359 (2.30%) 224 (2.41%) 135 (2.14%) 45 (2.28%) 62 (2.39%) 28 (1.59%)
 Surgery and radiotherapy 2885 (18.50%) 2054 (22.14%) 831 (13.15%) 331 (16.79%) 357 (13.77%) 143 (8.14%)

SEER=surveillance, epidemiology and end results; ESCC=esophageal squamous cell carcinoma; EAC=esophageal adenocarcinoma; TNM= tumor, node and metastasis.